Glioblastoma News and Research RSS Feed - Glioblastoma News and Research

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers have developed a new breakthrough combination treatment that utilizes a vaccine to activate an immune response against advanced brain tumors. [More]
Combined therapy approach could prove promising to treat brain cancer

Combined therapy approach could prove promising to treat brain cancer

A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say. [More]
Yale-led study shows how EGFR silences tumor suppressor genes

Yale-led study shows how EGFR silences tumor suppressor genes

A Yale-led study describes how a known cancer gene, EGFR, silences genes that typically suppress tumors. The finding, published in Cell Reports, may lead to the development of more effective, individualized treatment for patients with lung cancer and other cancer types. [More]
Researchers seek to develop novel antibody to treat glioblastoma

Researchers seek to develop novel antibody to treat glioblastoma

Scientists of Helmholtz Zentrum München and the Munich University Hospital are developing a novel antibody to treat brain tumors. [More]
Scientific paper supports concept of CarThera's intracranial ultrasound implant to disrupt blood-brain barrier

Scientific paper supports concept of CarThera's intracranial ultrasound implant to disrupt blood-brain barrier

CarThera, a French company based at the Brain and Spine Institute, that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces the publication in Science Translational Medicine of a scientific paper on initial successes in disrupting the blood-brain barrier (BBB) with the use of ultrasound. [More]
Four miRNAs may hold vital clue to disease progression in gliobastoma

Four miRNAs may hold vital clue to disease progression in gliobastoma

Scientists at the Helmholtz Zentrum München and the Ludwig Maximilians University of Munich have developed a new method of predicting disease progression in gliobastoma patients who have undergone standard treatment. [More]
New nano-fabricated platform provides accurate post-surgery prognosis for glioblastoma patients

New nano-fabricated platform provides accurate post-surgery prognosis for glioblastoma patients

A new nano-fabricated platform for observing brain cancer cells provides a much more detailed look at how the cells migrate and a more accurate post-surgery prognosis for brain cancer (glioblastoma) patients. [More]
Study underscores importance of developing PRMT5 inhibitors as promising treatment for GB patients

Study underscores importance of developing PRMT5 inhibitors as promising treatment for GB patients

A new study suggests that blocking an enzyme called PRMT5 in tumor cells could be a promising new strategy for the treatment of glioblastoma (GB), the most aggressive and lethal form of brain cancer. [More]
Johns Hopkins researchers develop lab test that accurately predicts glioblastoma aggression and spread

Johns Hopkins researchers develop lab test that accurately predicts glioblastoma aggression and spread

Johns Hopkins Medicine researchers report they have developed an experimental laboratory test that accurately clocks the “speed” of human brain tumor cell movement along a small glass “track.” [More]
UCLA scientists develop statistical method for conducting survival analysis of cancer patients

UCLA scientists develop statistical method for conducting survival analysis of cancer patients

People with cancer are often told by their doctors approximately how long they have to live, and how well they will respond to treatments, but what if there were a way to improve the accuracy of doctors' predictions? [More]
Giving chemotherapy after radiotherapy delays rare brain tumour growth

Giving chemotherapy after radiotherapy delays rare brain tumour growth

GIVING chemotherapy after radiotherapy delays further growth of a rare type of brain tumour, increasing the number of patients alive at five years from 44 per cent to 56 per cent. [More]
Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Patients with recurrent high-grade glioma brain tumors have few effective treatment options and the majority of available therapies do not improve survival. Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients. [More]
Retroviral replicating vector can extend lives of brain cancer patients

Retroviral replicating vector can extend lives of brain cancer patients

Doctors at UCLA, Cleveland Clinic, University of California San Diego School of Medicine and additional institutions have achieved a milestone in the development of a treatment for people with recurrent glioblastoma, the most common and aggressive form of brain cancer, by successfully demonstrating a modified virus that can extend the lives of patients with the disease. [More]
Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer. [More]
Specific immune system genes may determine how long people can live with glioblastoma

Specific immune system genes may determine how long people can live with glioblastoma

Researchers have identified a group of immune system genes that may play a role in how long people can live after developing a common type of brain cancer called glioblastoma multiforme, a tumor of the glial cells in the brain. [More]
Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline. [More]
Mitoxantrone for MS linked to colorectal cancer risk

Mitoxantrone for MS linked to colorectal cancer risk

Treatment with mitoxantrone for multiple sclerosis carries only a mildly increased risk of malignancy overall, but the risk of colorectal cancer and leukaemia is heightened, researchers have found. [More]
Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial. [More]
Small lipid nanocarrier may deliver chemotherapeutic drug more efficiently to brain tumor cells

Small lipid nanocarrier may deliver chemotherapeutic drug more efficiently to brain tumor cells

Great discoveries do come in small packages. Few know that better than Ann-Marie Broome, Ph.D., who feels nanotechnology holds the future of medicine with its ability to deliver powerful drugs in tiny, designer packages. [More]
Umea University researchers find link between vitamin E and brain tumours

Umea University researchers find link between vitamin E and brain tumours

Researchers at Umea University in Sweden and the Cancer Registry of Norway have studied possible causes behind the development of brain tumours. [More]
Advertisement
Advertisement